Barclays PLC Spectrum Pharmaceuticals Inc Put Options Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2020 Aug 12, 2020	SELL	$2.11 - $3.38 $1,055 - $1,690	-500 Reduced 10.0%	4,500 $15,000
Q1 2020 May 13, 2020	SELL	$1.83 - $3.45 $13,176 - $24,840	-7,200 Reduced 59.02%	5,000 $12,000
Q4 2019 Feb 10, 2020	BUY	$3.5 - $10.35 $9,100 - $26,910	2,600 Added 27.08%	12,200 $44,000
Q3 2019 Nov 14, 2019	SELL	$7.03 - $9.7 $1.52 Million - $2.1 Million	-216,300 Reduced 95.75%	9,600 $80,000
Q2 2019 Aug 14, 2019	BUY	$7.36 - $11.26 $1.64 Million - $2.51 Million	222,900 Added 7430.0%	225,900 $1.95 Million
Q1 2019 May 15, 2019	BUY	$9.08 - $11.84 $12,712 - $16,576	1,400 Added 87.5%	3,000 $32,000
Q4 2018 Feb 14, 2019	SELL	$6.39 - $16.99 $159,111 - $423,050	-24,900 Reduced 93.96%	1,600 $14,000
Q3 2018 Nov 14, 2018	BUY	$16.52 - $24.82 $409,696 - $615,536	24,800 Added 1458.82%	26,500 $445,000
Q2 2018 Aug 14, 2018	SELL	$14.31 - $21.75 $54,378 - $82,650	-3,800 Reduced 69.09%	1,700 $36,000
Q1 2018 May 15, 2018	BUY	$16.09 - $23.07 $1,609 - $2,307	100 Added 1.85%	5,500 $88,000
Q4 2017 Feb 14, 2018	BUY	$13.36 - $20.73 $72,144 - $111,942	5,400	5,400 $102,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.